Next Article in Journal
Live Cell Imaging by Förster Resonance Energy Transfer Fluorescence to Study Trafficking of PLGA Nanoparticles and the Release of a Loaded Peptide in Dendritic Cells
Next Article in Special Issue
Protective Mechanism Pathway of Swietenia macrophylla Extract Nanoparticles against Cardiac Cell Damage in Diabetic Rats
Previous Article in Journal
Mast Cells as a Potential Target of Molecular Hydrogen in Regulating the Local Tissue Microenvironment
Previous Article in Special Issue
Respiratory Outcomes of Insulin Use in Patients with COPD: A Nationwide Population-Based Cohort Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 16
Issue 6
10.3390/ph16060819
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Pharmaceuticals 2022, 15(11), 1442.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Liu et al. Apigenin Ameliorates Hyperuricemia and Renal Injury through Regulation of Uric Acid Metabolism and JAK2/STAT3 Signaling Pathway. Pharmaceuticals 2022, 15, 1442

by
Tianyuan Liu
1,†,
Huimin Gao
2,†,
Yueyi Zhang
1,
Shan Wang
1,
Meixi Lu
1,
Xuan Dai
1,
Yage Liu
1,
Hanfen Shi
1,
Tianshu Xu
1,
Jiyuan Yin
1,
Sihua Gao
1,
Lili Wang
3,* and
Dongwei Zhang
1,*
1
Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing 100029, China
2
Institute of Chinese Materia Medica, China Academy of Chinese Medical Science, Beijing 100700, China
3
Department of TCM Pharmacology, Chinese Material Medica School, Beijing University of Chinese Medicine, Beijing 102488, China
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Pharmaceuticals 2023, 16(6), 819; https://doi.org/10.3390/ph16060819
Submission received: 30 April 2023 / Accepted: 18 May 2023 / Published: 31 May 2023
(This article belongs to the Special Issue Drug Candidates for the Treatment of Metabolic Syndrome)
Browse Figures
Versions Notes

Error in Figure

In the original publication [1], there were mistakes in Figures 5 and 9 as published. In Figure 5C, the molecular weight of URAT1 protein was labeled incorrectly. The correct size of URAT1 protein in this experiment should be 46 KDa. In Figure 9, the dosage of hypoxanthine (Hypox) was incorrectly stated in the original publication. The dosage of Hypox should be 500 mg/kg. The corrected Figure 5 and Figure 9 appear below.

Text Correction

There was an error in the original publication. The dosage of hypoxanthine (Hypox) was incorrectly stated in the original publication. The dosage of Hypox should be 500 mg/kg.
A correction has been made to Section 3. Discussion, Paragraph 8:
“In this study, Allop was demonstrated to decrease the levels of liver XOD and serum UA, and increase the levels of urine CRE (day 6) in this rapid HUA mouse model. However, Allop did not reverse the increased serum levels of CRE and BUN in HUA mice. By contrast, Chen et al. [64] reported that Allop was able to decrease serum levels of CRE and BUN in HUA mice. The underlying cause to explain the conflicting findings may be attributed to the differences in the approaches to establish HUA mouse model. In their study, the authors employed intraperitoneal injection with PO to establish the HUA mouse model. However, in the present study, Hypox (500 mg/kg, gavage) was used to induce HUA mice in addition to PO exposure.”
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Liu, T.; Gao, H.; Zhang, Y.; Wang, S.; Lu, M.; Dai, X.; Liu, Y.; Shi, H.; Xu, T.; Yin, J.; et al. Apigenin Ameliorates Hyperuricemia and Renal Injury through Regulation of Uric Acid Metabolism and JAK2/STAT3 Signaling Pathway. Pharmaceuticals 2022, 15, 1442. [Google Scholar] [CrossRef] [PubMed]
Pharmaceuticals 16 00819 g001 550
Figure 5. Apigenin decreases liver XOD levels (A; U/g, n = 10) and renal expression levels of GLUT9 and URAT1, and increases renal expression levels of OAT1 in HUA mice. Representative images of western blot and their analyses show GLUT9 (B), URAT1 (C), and OAT1 (D) expressions in the kidneys (n ≥ 3). ## p < 0.01, # p < 0.05 vs. the NC group. ** p < 0.01, * p < 0.05 vs. the HC group.
Figure 5. Apigenin decreases liver XOD levels (A; U/g, n = 10) and renal expression levels of GLUT9 and URAT1, and increases renal expression levels of OAT1 in HUA mice. Representative images of western blot and their analyses show GLUT9 (B), URAT1 (C), and OAT1 (D) expressions in the kidneys (n ≥ 3). ## p < 0.01, # p < 0.05 vs. the NC group. ** p < 0.01, * p < 0.05 vs. the HC group.
Pharmaceuticals 16 00819 g001
Pharmaceuticals 16 00819 g002 550
Figure 9. Experimental design on action of apigenin on acute HUA mice. ig denotes intragastrical administration, ip denotes intraperitoneal administration.
Figure 9. Experimental design on action of apigenin on acute HUA mice. ig denotes intragastrical administration, ip denotes intraperitoneal administration.
Pharmaceuticals 16 00819 g002
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Liu, T.; Gao, H.; Zhang, Y.; Wang, S.; Lu, M.; Dai, X.; Liu, Y.; Shi, H.; Xu, T.; Yin, J.; et al. Correction: Liu et al. Apigenin Ameliorates Hyperuricemia and Renal Injury through Regulation of Uric Acid Metabolism and JAK2/STAT3 Signaling Pathway. Pharmaceuticals 2022, 15, 1442. Pharmaceuticals 2023, 16, 819. https://doi.org/10.3390/ph16060819

AMA Style

Liu T, Gao H, Zhang Y, Wang S, Lu M, Dai X, Liu Y, Shi H, Xu T, Yin J, et al. Correction: Liu et al. Apigenin Ameliorates Hyperuricemia and Renal Injury through Regulation of Uric Acid Metabolism and JAK2/STAT3 Signaling Pathway. Pharmaceuticals 2022, 15, 1442. Pharmaceuticals. 2023; 16(6):819. https://doi.org/10.3390/ph16060819

Chicago/Turabian Style

Liu, Tianyuan, Huimin Gao, Yueyi Zhang, Shan Wang, Meixi Lu, Xuan Dai, Yage Liu, Hanfen Shi, Tianshu Xu, Jiyuan Yin, and et al. 2023. "Correction: Liu et al. Apigenin Ameliorates Hyperuricemia and Renal Injury through Regulation of Uric Acid Metabolism and JAK2/STAT3 Signaling Pathway. Pharmaceuticals 2022, 15, 1442" Pharmaceuticals 16, no. 6: 819. https://doi.org/10.3390/ph16060819

APA Style

Liu, T., Gao, H., Zhang, Y., Wang, S., Lu, M., Dai, X., Liu, Y., Shi, H., Xu, T., Yin, J., Gao, S., Wang, L., & Zhang, D. (2023). Correction: Liu et al. Apigenin Ameliorates Hyperuricemia and Renal Injury through Regulation of Uric Acid Metabolism and JAK2/STAT3 Signaling Pathway. Pharmaceuticals 2022, 15, 1442. Pharmaceuticals, 16(6), 819. https://doi.org/10.3390/ph16060819

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop